IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2018
At a glance
- Drugs AGS 004 (Primary) ; Vorinostat (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms VORVAX
- 17 Apr 2018 Planned End Date changed from 1 Dec 2019 to 1 Feb 2021.
- 17 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Feb 2021.
- 02 Apr 2018 According to an Argos Therapeutics Inc media release, the company expect to report early results by the end of 2018 or early 2019.